argenx SE (ARGX) Plans to Move ARGX-119 into a Registrational Study

argenx SE (NASDAQ:ARGX) is one of the Best Extremely Profitable Stocks to Buy Right NowOn June 30, argenx SE (NASDAQ:ARGX) announced its plans to move its experimental drug ARGX-119 into a registrational study for congenital myasthenic syndromes. This decision comes after positive results from a Phase 1b clinical trial.

ARGX-119 is a novel antibody targeting muscle-specific kinase. It’s designed to help patients with congenital myasthenic syndromes. The Phase 1b trial tested ARGX-119 against a placebo in patients with DOK7-CMS, a critically affected subgroup. The results showed that patients receiving ARGX-119 consistently improved on indicators including walking ability, muscle strength, and activities of daily living.

argenx SE (ARGX) Plans to Move ARGX-119 into a Registrational Study

A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.

argenx SE (NASDAQ:ARGX) is a biopharmaceutical company that develops innovative antibody therapies to treat severe autoimmune diseases and cancer.

While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.